-
MASLD/MASH: Clinical and Economic Findings from 40-year Follow-Up Data
Dec 10, 2024, 11:14 AM -
Leveraging the Value of Clinical Outcomes in DMD for Decision Making
Dec 4, 2024, 13:20 PM -
The Burden of Time: MS Treatment and Socio-Economic Impact Reduction
Oct 30, 2024, 15:17 PM -
IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings
Oct 22, 2024, 15:12 PM -
Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?
Oct 16, 2024, 15:01 PM -
Global Perspective on Inequality Aversion: Methods and Learnings
Oct 16, 2024, 11:32 AM -
Patient Involvement in Value and Health Technology Assessment (V/HTA)
Oct 10, 2024, 15:05 PM -
Conducting Research and Survey Studies in Hard-to-Reach Populations
Oct 9, 2024, 14:05 PM -
Can GenAI for Literature Reviews Ever Be Trusted? A Pragmatic Approach That’s Ethically Designed and Purpose-built for HEOR Professionals
Oct 3, 2024, 16:38 PM -
Transferability of Data and Methods to Central and Eastern Europe
Sep 19, 2024, 12:53 PM -
Moving Toward Universal Health Coverage in Africa: The Role of HTA
Aug 22, 2024, 14:15 PM -
The Role of RWE for Devices and Diagnostic Market Access in Europe
Jul 9, 2024, 12:44 PM -
ISPOR Top 10 HEOR Trends - What Are the Key Themes for 2024-2025?
Jun 12, 2024, 13:19 PM -
Overcoming the Barriers of Open-Source Modeling
Jun 11, 2024, 14:37 PM -
Assessing the Fiscal Burden of Obesity Using a Public Economic Framework
May 30, 2024, 13:20 PM -
Are Clinical Outcome Assessments Sufficiently Valued?
May 29, 2024, 15:21 PM -
The Global Socioeconomic Impact of Rare Diseases: A Call for Action
May 22, 2024, 12:35 PM -
Revolutionizing Systematic Reviews: Harnessing the Power of AI
May 21, 2024, 10:54 AM -
Revolutionizing Clinical Trials: Harnessing Real-World Evidence to Drive Diversity and Clinical Implementation
Apr 11, 2024, 14:15 PM -
Measuring the Indirect Costs Driving Financial Toxicity in Oncology
Apr 8, 2024, 16:02 PM